Go Deep
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,123 | 50.7 | 4.63 | 0.07 | 8,228.58 |
| Oct 2026 | 19,027 | 51.4 | 4.69 | 0.07 | 8,271.02 |
| Oct 2026 | 19,149 | 50.8 | 4.63 | 0.07 | 8,120.58 |
| Oct 2026 | 19,055 | 51.5 | 4.69 | 0.07 | 8,208.21 |
| Oct 2026 | 18,924 | 51.8 | 4.78 | 0.07 | 8,366.07 |
| Oct 2026 | 19,043 | 51.5 | 4.70 | 0.07 | 8,202.31 |
| Oct 2026 | 18,994 | 51.9 | 4.74 | 0.07 | 8,269.89 |
| Oct 2026 | 18,909 | 52.6 | 4.79 | 0.07 | 8,371.34 |
| Oct 2026 | 18,900 | 52.6 | 4.80 | 0.07 | 8,361.06 |
| Oct 2026 | 18,765 | 53.6 | 4.89 | 0.07 | 8,503.67 |
| Oct 2026 | 18,846 | 53.0 | 4.83 | 0.07 | 8,442.25 |
Edwards Lifesciences Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,741,000,000.0 | 1,648,600,000.0 | 1,569,600,000.0 | 1,553,100,000.0 |
| Net Profit | 241,900,000.0 | 380,700,000.0 | 91,200,000.0 | 291,100,000.0 |
| EPS | 0.4 | 0.7 | 0.2 | 0.5 |
Edwards Lifesciences Corporation Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 6,067,600,000.0 | 5,439,500,000.0 | 5,010,000,000.0 | 4,464,000,000.0 | — |
| Net Profit | 1,073,500,000.0 | 4,174,600,000.0 | 1,402,400,000.0 | 1,521,900,000.0 | — |
| EPS | 1.8 | 7.0 | 2.3 | 2.5 | — |
Edwards Lifesciences Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 13,697,200,000.0 | 13,055,300,000.0 | 9,363,200,000.0 | 8,292,500,000.0 | — |
| Total Liabilities | 3,359,600,000.0 | 2,992,400,000.0 | 2,643,800,000.0 | 2,485,800,000.0 | — |
| Total Equity | 10,337,600,000.0 | 9,998,400,000.0 | 6,650,000,000.0 | 5,806,700,000.0 | — |
Owes vs Owns
Edwards Lifesciences Corporation owed $0.23 for every $1 it owned in Jun 2026, down from $0.30 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.23× | 0.25× | 0.23× | 0.28× | 0.30× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Edwards Lifesciences Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 30.9%Receivables 6.7%Inventory 8.2%Fixed assets (tangible) 14.0%Intangible assets 21.1%Long-term investments 2.0%Other assets 17.1%
How it's funded — Dec 2025
Long-term debt 4.4%Payables 1.7%Other liabilities 18.3%Shareholders' equity 75.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 4,226.3 | 3,975.9 | 1,632.8 | 1,215.3 |
| Receivables | 912.1 | 727.4 | 828.1 | 699.1 |
| Inventory | 1,126.2 | 1,086.7 | 903.5 | 875.5 |
| Fixed assets (tangible) | 1,914.6 | 1,784.2 | 1,675.4 | 1,725.1 |
| Intangible assets | 2,896.8 | 2,953.3 | 1,544.5 | 1,449.5 |
| Long-term investments | 278.6 | 307.9 | 583.9 | 1,239.0 |
| Other assets | 2,342.6 | 2,219.9 | 2,195.0 | 1,089.0 |
| Liabilities & equity | ||||
| Short-term debt | 24.5 | 23.4 | 22.9 | 25.5 |
| Long-term debt | 598.3 | 597.7 | 597.0 | 596.3 |
| Payables | 227.5 | 197.4 | 186.6 | 201.9 |
| Other liabilities | 2,509.3 | 2,173.9 | 1,837.3 | 1,662.1 |
| Shareholders' equity | 10,337.6 | 10,062.9 | 6,719.4 | 5,806.7 |
| Net tangible assets | 7,440.8 | 7,045.1 | 5,105.5 | 4,357.2 |
Edwards Lifesciences Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 1,595,200,000.0 | 542,300,000.0 | 895,800,000.0 | 1,218,200,000.0 | — |
| Investing Activities | -712,900,000.0 | 2,312,900,000.0 | 173,800,000.0 | 252,300,000.0 | — |
| Financing Activities | -956,800,000.0 | -983,000,000.0 | -711,000,000.0 | -1,584,500,000.0 | — |